CelLBxHealth Statistics
Total Valuation
CelLBxHealth has a market cap or net worth of 16.25 million. The enterprise value is 14.07 million.
| Market Cap | 16.25M |
| Enterprise Value | 14.07M |
Important Dates
The next estimated earnings date is Monday, June 1, 2026.
| Earnings Date | Jun 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 321.53M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +22.34% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 3.44% |
| Owned by Institutions (%) | 18.63% |
| Float | 753.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.52 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.65 |
| EV / Sales | 3.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.88 |
Financial Position
The company has a current ratio of 3.13, with a Debt / Equity ratio of 0.31.
| Current Ratio | 3.13 |
| Quick Ratio | 2.63 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.32 |
| Interest Coverage | -51.36 |
Financial Efficiency
Return on equity (ROE) is -87.18% and return on invested capital (ROIC) is -46.31%.
| Return on Equity (ROE) | -87.18% |
| Return on Assets (ROA) | -39.98% |
| Return on Invested Capital (ROIC) | -46.31% |
| Return on Capital Employed (ROCE) | -109.37% |
| Weighted Average Cost of Capital (WACC) | 5.84% |
| Revenue Per Employee | 30,210 |
| Profits Per Employee | -181,676 |
| Employee Count | 119 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | -993,287 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.57% in the last 52 weeks. The beta is 0.23, so CelLBxHealth's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -89.57% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 33.89 |
| Average Volume (20 Days) | 14,090 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CelLBxHealth had revenue of 3.60 million and -21.62 million in losses. Loss per share was -0.07.
| Revenue | 3.60M |
| Gross Profit | 1.13M |
| Operating Income | -22.38M |
| Pretax Income | -22.61M |
| Net Income | -21.62M |
| EBITDA | -21.30M |
| EBIT | -22.38M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 7.22 million in cash and 5.02 million in debt, with a net cash position of 2.20 million.
| Cash & Cash Equivalents | 7.22M |
| Total Debt | 5.02M |
| Net Cash | 2.20M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 16.02M |
| Book Value Per Share | 0.05 |
| Working Capital | 9.20M |
Cash Flow
In the last 12 months, operating cash flow was -15.41 million and capital expenditures -505,549, giving a free cash flow of -15.92 million.
| Operating Cash Flow | -15.41M |
| Capital Expenditures | -505,549 |
| Free Cash Flow | -15.92M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 31.36% |
| Operating Margin | -622.48% |
| Pretax Margin | -629.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CelLBxHealth does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.34% |
| Shareholder Yield | -22.34% |
| Earnings Yield | -133.01% |
| FCF Yield | -97.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CelLBxHealth has an Altman Z-Score of -10.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.16 |
| Piotroski F-Score | 2 |